Healthcare Mergers, Acquisitions & Ventures Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions & Ventures Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biogen Idec Inc.
Biogen Idec Extends Offer to Acquire Facet Biotech Corporation for $14.50 Per Share in Cash
November 7th, 2009
Biogen Idec Inc. (NASDAQ:BIIB) announced that it has extended the tender offer by its wholly owned subsidiary, FBC Acquisition Corp., to purchase all of the outstanding shares of Facet Biotech Corporation (NASDAQ: FACT) to 12:00 midnight New York City time on December 16, 2009, unless otherwise extended. The tender offer was previously set to expire at 12:00 midnight New York City time on October 19, 2009. "Our offer price remains unchanged at $14.50 per share in cash, which is a substantial premium to where Facet Biotech's stock was trading prior to our offer," said Biogen Idec's President and Chief Executive Officer James C. Mullen. "We continue to believe our offer...
Source: Healthcare Mergers, Acquisitions & Ventures Week (2009-11-07)
|
